In this section, we cover the recent EMA approval of zanubrutinib for multiple indications, explore the promising outcomes of fixed-duration ibrutinib + venetoclax in untreated CLL/SLL patients and delve into the long-term benefits of acalabrutinib in first-line CLL treatment. Additionally, we report the approval of Pirtobrutinib (Jaypirca®) for relapsed/refractory mantle cell lymphoma, and the emergence of axicabtagene ciloleucel as the new standard of care for second-line treatment in DLBCL patients.
Stay informed with the latest developments and dive into our Pharma News section!
